The top 10 research priorities for pancreatitis: findings from a James Lind Alliance priority setting partnership
- PMID: 37356452
- DOI: 10.1016/S2468-1253(23)00151-6
The top 10 research priorities for pancreatitis: findings from a James Lind Alliance priority setting partnership
Conflict of interest statement
The James Lind Alliance priority setting partnership dealing with the diagnosis, treatment, and care of people with pancreatitis was funded equally by the Guts UK Charity, the British Society of Gastroenterology, and the Pancreatic Society of Great Britain and Ireland. JL has received research funding and honoraria from Viatris for teaching. DMis a founder director of Kynos Therapeutics and APPreSci (neither of which have products in development for pancreatitis), and has received consulting fees from GSK, Calcimedica, Medixci, FlexWave Medical, Healthcare Ventures, Phoenix Group, and Epidarex Capital. MP has received honoraria for teaching and advisory panel membership from Viatris and Nutricia Clinical Care. AH has received honoraria for teaching and resource development from Mylan. SM has received honoraria for teaching via webinar from Viatris 2020, and for reviewing information materials from the Guts UK charity in 2022. MT was paid a professional fee as the independent James Lind adviser for this priority setting partnership. All other authors declared no competing interests. We thank all the people with pancreatitis, relatives, carers, and health-care professionals who took part in this priority setting partnership, including the final workshop.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
